|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
GSK-3β could directly phosphorylate 4EBP1 and activate the mTORC1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in RCC cell lines independent of rapamycin sensitivity.
|
27387559 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of mTOR is an established therapeutic principle in transplantation medicine and in cancers, such as renal cell carcinoma.
|
22125056 |
2012 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance.
|
27863441 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
There has been a recent expansion of therapeutic options in metastatic renal cell carcinoma (RCC) targeted at the vascular endothelial growth factor and mammalian target of rapamycin pathways, which are fundamental to the biology of RCC.
|
19470934 |
2009 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The inhibition of proangiogenic factors and mTOR was the main idea behind the development of new targeted agents in advanced RCC.
|
17935273 |
2007 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, mammalian target of rapamycin (mTOR), an intracellular serine/threonine kinase, is also implicated in HIF-1a regulation, thus reinforcing the rationale for using mTOR inhibitors (rapamycin) in CCRCC.
|
20437403 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved.
|
28276433 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients.
|
31031856 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Currently, targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors are widely used in the treatment of metastatic RCC.
|
29323560 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI).
|
29120911 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to investigate whether the activity of the mTOR inhibitor temsirolimus against RCC could be enhanced by OGX-011, an antisense oligodeoxynucleotide (ODN) targeting the stress-activated chaperone clusterin.
|
27526062 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A significant early discovery in RCC was frequent inactivation of the Von Hippel Lindau gene in ccRCC, which ultimately led to the development of vascular endothelial growth factor and mammalian target of rapamycin inhibitors.
|
30478013 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor that exhibits antitumor activity in renal cell carcinoma and mantle cell lymphoma.
|
28676933 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The relevant literature was reviewed concerning pathways implicated in the pathophysiology of renal cell carcinoma including pathways activated secondary to von Hippel-Lindau gene inactivation and PI-3 kinase/Akt/mammalian target of rapamycin pathway activation.
|
16336094 |
2005 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|